Search - tctmd.com

Displaying 221 - 240 of 430

Sort: Relevancy | Date

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

Todd Neale

August 13, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

Presenter: Allen Jeremias

May 06, 2018

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Michael O'Riordan

February 27, 2018

News Daily News

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Yael L. Maxwell

January 31, 2018

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Todd Neale

January 25, 2018

Advertisement

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Once Again, ISCHEMIA Trial Feels the Squeeze

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Combined analysis of DEFINE-FLAIR and iFR Swedeheart: Safety of PCI deferral in stable CAD and ACS

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content